Thrivelab’s menopause page says a clinician may choose estrogen, progesterone or neither. That framing matters when the question is why another medicine is being proposed. The answer should come from the intended treatment goal and relevant history, rather than from the presence of a hormone in a price list.
This review is dated September 29, 2026. It considers the menopause service description, FAQ and medicine-price record, including qualifications and differences between them. It does not establish an individual clinical assessment, selected pharmacy preparation, current stock or patient outcome.
The service leaves room for a different explanation of symptoms
Thrivelab’s menopause description names the possibility of prescribing neither estrogen nor progesterone. It also separates a weight concern from an automatic increase in estrogen and describes considering other contributors. These are statements about the provider’s approach, not proof that any reader has a hormone deficiency or needs a particular investigation.
The distinction gives the consultation a question more useful than which product to buy: what is the clinician trying to address? Joi’s review examines broad progesterone benefit language from a different provider. Comparing the explanations does not rank clinical outcomes; neither service was tested through patient care for this review.
Relevant dates and history should connect to the reason for treatment
The service page explicitly identifies age, time since the last period, clot history, migraine, cancer history and the patient’s goals as relevant. That supports saying the provider publicly discusses those factors. It does not verify every question in an actual intake or the decision a clinician would make.
The hysterectomy discussion adds another history issue without converting it into a treatment rule. ACOG’s explanation of surgery distinguishes what happens to the uterus, cervix and ovaries. The useful record is the operation and relevant history, rather than an assumption that one remembered procedure name supplies the whole prescribing answer.
The estrogen category has to be known before discussing an addition
FDA’s current therapy overview distinguishes systemic treatment from topical vaginal estrogen. A route name alone can be incomplete: its categories include vaginal rings in different treatment contexts. The exact product therefore matters when discussing exposure and purpose.
Our systemic-estrogen guide and local-vaginal-treatment guide keep those questions separate. Thrivelab’s broad list of delivery forms does not assign every hormone to every form or establish a personal need for progesterone. A clinician’s proposal should explain both the intended effect of the estrogen product and the role, if any, of an accompanying medicine. The public menu cannot make that connection for an unidentified prescription.
A detailed medicine table still does not identify the final preparation
The published price list contains progesterone entries and combinations with ingredients such as melatonin or theanine. Its records carry differing 2024 and 2025 dates. Abbreviations including SR, SB and E4M are not interpreted here as a complete formulation specification.
A combination entry is not equivalent to progesterone alone, and its presence does not establish that treating sleep is appropriate for a particular patient. The FAQ discusses compounded prescriptions; FDA explains that compounded medicines are not FDA-approved. The table cannot supply the exact ingredients, current dispensing pharmacy, approval status or evidence for a preparation that has not yet been identified. A historical item price also does not establish today’s quantity, shipping charge or refill commitment. Those purchase details cannot be inferred from the presence of a similar hormone name in a lengthy table.
Testing and geographic statements need clarification within the selected service
The care description says testing confirms the plan before prescribing, while the FAQ says treatment can begin without laboratory work. Those statements are not reconciled by this review into a personal testing instruction. The clinician would need to explain what is required for the proposed care and why.
The care page’s nationwide delivery wording also sits beside location limitations in the FAQ. A general national statement should not be treated as proof of access for every state and circumstance. Alloy’s review examines another offer with specific qualifications. Here, confirmation of the selected service remains necessary before assuming availability, testing costs or a prescription.
Care fees, medicine ranges and missed-visit charges use different units
The FAQ describes a general medicine range of $80–$140 per month, not a verified progesterone-only price. Self-pay care is shown at $49 per month paid quarterly or $40 per month paid annually, plus $45 per telehealth visit. A separately stated $94 initial appointment is not reconciled into an assumed combined checkout total.
The same record describes $84 for initial missed appointments or cancellations and rescheduling within forty-eight hours, and $15 for existing patients. Refunds are considered case by case for clinical care or appointment fees; partial Thrively payments and prescriptions are excluded. These conditions belong beside the prices. They do not establish personal insurance coverage or make clinical benefit a guaranteed purchase outcome.
The route for reassessment should extend beyond the hormone explanation
Thrivelab’s menopause page says bleeding after a long interval may require an in-person gynecologist and should not wait for an annual review. ACOG’s bleeding information similarly supports professional evaluation of bleeding after menopause and abnormal changes around it.
Our unexpected-bleeding guide cannot assess the cause or produce an adjustment to treatment. Thrivelab’s relevant service is documented, but a satisfactory explanation still has to connect the chosen medicine, history and intended goal with a practical clinical contact. A table entry, a support promise or an existing progesterone prescription cannot answer a new medical concern on its own.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Thrivelab: Menopause hormone careProvider clinical-service description; treatment and access wording is not an individual prescribing or state-eligibility confirmation · Checked 2026-09-29
- ACOG: HysterectomyUS specialty patient guidance; uterus, cervix and ovary procedures distinguished, no treatment decision from surgery name alone · Checked 2026-09-29
- FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal categories and product-specific warning-change context; systemic estrogen and topical vaginal therapy distinguished, no class-wide warning conclusion · Checked 2026-09-29
- Thrivelab: Medication pricesProvider medication tables dated April 5, 2024 and February 19, 2025; current page access does not update historical prices or explain formulation codes · Checked 2026-09-29
- Thrivelab: Frequently asked questionsProvider FAQ; separate membership, medication, state-access, laboratory and refund descriptions retain their stated limits · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29